Business
Artivion Reports Fourth Quarter and Full Year 2025 Financial Results
Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the fourth quarter and year ended December 31, 2025.
About this update from Artivion, Inc.
[{"type":"text","content":"Fourth Quarter Highlights: ","length":26,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"GAAP revenue was $116.0 million in the fourth quarter of 2025 versus $97.3 million in the fourth quarter of 2024. For the full year, GAAP revenue was $441.3 million versus $388.5 million for the full year of 2024. GAAP net income was $2.4 million, or $0.05 per fully diluted share, in the fourth quarter of 2025, versus a net loss of $(16.5) million, or $(0.39) per fully diluted share in the fourth quarter of 2024. For the full year 2025, GAAP net income was $9.8 million, versus a net loss of $(13.4) million for the full year 2024.","length":535,"tagName":"p"}]},{"val":[{"type":"text","content":"Adjusted revenue1 was $118.3 million in the fourth quarter of 2025, an increase of 18% on an adjusted constant currency basis compared to the fourth quarter of 2024.","length":165,"tagName":"p"}]},{"val":[{"type":"text","content":"Adjusted revenue1 was $443.6 million for the full year 2025, an increase of 13% on an adjusted constant currency basis compared to the full year of 2024.","length":153,"tagName":"p"}]},{"val":[{"type":"text","content":"Non-GAAP net income was $8.6 million, or $0.17 per fully diluted share in the fourth quarter of 2025. For the full year, non-GAAP net income was $29.7 million.","length":159,"tagName":"p"}]},{"val":[{"type":"text","content":"Adjusted EBITDA increased 29% to $22.7 million in the fourth quarter of 2025 compared to $17.6 million in the fourth quarter of 2024. For the full year adjusted EBITDA increased 26% to $89.6 million.","length":199,"tagName":"p"}]},{"val":[{"type":"text","content":"Positive new clinical data from Endospan's NEXUS TRIOMPHE IDE trial presented at the STS Annual Meeting demonstrate high patient survival with low morbidity.","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"Filed the fourth and final module of the pre-market approval application (PMA) to the FDA for the AMDS Hybrid Prothesis.","length":120,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1492,"olType":false},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"1","rowspan":"1","style":"PADDING-RIGHT:0.17em;PADDING-LEFT:0.17em;VERTICAL-ALIGN:BOTTOM;","val":[{"type":"text","content":"","length":0,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","style":"PAD...